TNF and myositis disease: Biological agents have also been tested in myositis: at first, Intravenous (IV) immunoglobulins, considered to present immunomodulatory properties, and then monoclonal antibodies, such as Rituximab (anti-CD20), Tocilizumab (anti-IL-6), Infliximab (anti-TNFα), Alemtuzumab (anti-CD52), Basiliximab (anti-IL-2R) or Sifalimumab (anti-IFNα), or even receptor antagonist Anakinra (anti-IL-1R), JAK inhibitor Tofacitinib and fusion proteins Abatacept or Etanercept, which block CTLA-4 or TNFα pathways, respectively [6, 80, 81].